News

STELARA is the first biologic therapy for Crohn’s disease targeting interleukin (IL)-12 and IL-23 cytokines, which play a key role in inflammatory and immune responses. William J. Sandborn, MD,

In this trial, Epidiolex, when added to the patient’s current treatment, achieved the primary endpoint for both dose levels with high statistical significance. During the treatment period, patients

Sanofi Pasteur committed to researching and developing a vaccine to prevent Zika in February, shortly after the World Health Organization declared an emergency. In July 2016, Sanofi Pasteur

The acquisition is expected to close in the next three weeks.  Terms of the transaction were not disclosed. Established in 1995, ExecuPharm provides clients with qualified professionals across

The US drugmaker said its analysis determined that splitting Pfizer Innovative Health and Pfizer Essential Health would not improve cash flow or better position the businesses competitively. The

The parties hope to complete the deal in Q1 2017.  Pharmaron sees this as a unique opportunity to acquire state-of-the-art Good Manufacturing Practice (GMP) standard facilities for the

The multicenter, randomized Phase 2 trial is evaluating eryaspase as a second-line treatment of patients with metastatic pancreatic cancer. In the study conducted in France, eryaspase was added

The company has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) based on the data from the phase 3 Sirround clinical development

The approvals for the new indications, tumor necrosis factor-receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) and familial Mediterranean fever (FMF), were based on clinical